X
[{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Bioresearch Awarded $2.9 Million Fast-Track SBIR Grant for Development of Novel Therapy for Apathy in Alzheimer\u2019s Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Invitae","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invitae\u2019s Real-World Ciitizen Data Utilized in Praxis Precision Medicines\u2019 PRAX-222 IND Filing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Praxis Bioresearch
Filters
Companies By Therapeutic Area
Details:
PRAX-222 is an ASO designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations.
Lead Product(s):
PRAX-222
Therapeutic Area: Genetic Disease
Product Name: PRAX-222
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Invitae
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 20, 2022
Details:
The prodrug PRX-P4-003 serves as a substrate of pancreatic lipase, an enzyme whose biological activity is almost entirely restricted to the gut and thus is not expected to be activated by parenteral routes.
Lead Product(s):
PRX-P4-003
Therapeutic Area: Psychiatry/Psychology
Product Name: PRX-P4-003
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 09, 2021
Details:
PRX-P4-003 is a new chemical entity (US Patent 10,662,146) designed by Praxis to be an abuse resistant, once-a-day medicine to treat apathy caused by Alzheimer’s disease as well as other diseases requiring dopaminergic stimulant activity.
Lead Product(s):
PRX-P4-003
Therapeutic Area: Psychiatry/Psychology
Product Name: PRX-P4-003
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Institutes of Health
Deal Size: $2.9 million
Upfront Cash: Undisclosed
Deal Type: Funding
August 05, 2021